Literature DB >> 22689991

A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer.

Michael Herfs1, Yusuke Yamamoto, Anna Laury, Xia Wang, Marisa R Nucci, Margaret E McLaughlin-Drubin, Karl Münger, Sarah Feldman, Frank D McKeon, Wa Xian, Christopher P Crum.   

Abstract

Infection by carcinogenic human papillomaviruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers near the ectoendocervical squamocolumnar (SC) junction of the cervix. However, the specific cells targeted by HPV have not been identified and the cellular origin of cervical cancer remains elusive. In this study, we uncovered a discrete population of SC junctional cells with unique morphology and gene-expression profile. We also demonstrated that the selected junctional biomarkers were expressed by a high percentage of high-grade CIN and cervical cancers associated with carcinogenic HPVs but rarely in ectocervical/transformation zone CINs or those associated with noncarcinogenic HPVs. That the original SC junction immunophenotype was not regenerated at new SC junctions following excision, not induced by expression of viral oncoproteins in foreskin keratinocytes, and not seen in HPV-related precursors of the vagina, vulva, and penis further support the notion that junctional cells are the source of cervical cancer. Taken together, our findings suggest that carcinogenic HPV-related CINs and cervical cancers are linked to a small, discrete cell population that localizes to the SC junction of the cervix, expresses a unique gene expression signature, and is not regenerated after excision. The findings in this study uncover a potential target for cervical cancer prevention, provide insight into the risk assessment of cervical lesions, and establish a model for elucidating the pathway to cervical cancer following carcinogenic HPV infection.

Entities:  

Mesh:

Year:  2012        PMID: 22689991      PMCID: PMC3387104          DOI: 10.1073/pnas.1202684109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Cervical intraepithelial neoplasia III: long-term outcome after cold-knife conization with clear margins.

Authors:  O Reich; H Pickel; M Lahousen; K Tamussino; R Winter
Journal:  Obstet Gynecol       Date:  2001-03       Impact factor: 7.661

Review 3.  Cervical intraepithelial neoplasia.

Authors:  R M Richart
Journal:  Pathol Annu       Date:  1973

4.  An analysis of "long-term" follow-up results in patients with cervical intraepithelial neoplasia treated by cryotherapy.

Authors:  R M Richart; D E Townsend; W Crisp; A DePetrillo; A Ferenczy; G Johnson; G Lickrish; M Roy; U Villa Santa
Journal:  Am J Obstet Gynecol       Date:  1980-08-01       Impact factor: 8.661

5.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

6.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

Authors:  J Mork; A K Lie; E Glattre; G Hallmans; E Jellum; P Koskela; B Møller; E Pukkala; J T Schiller; L Youngman; M Lehtinen; J Dillner
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

7.  Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia.

Authors:  J T Keating; A Cviko; S Riethdorf; L Riethdorf; B J Quade; D Sun; S Duensing; E E Sheets; K Munger; C P Crum
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

8.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.

Authors:  Joel M Palefsky; Anna R Giuliano; Stephen Goldstone; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard Hillman; Daron Ferris; Francois Coutlee; Mark H Stoler; J Brooke Marshall; David Radley; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

9.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  130 in total

Review 1.  Cervical cancer stem cells.

Authors:  Tingting Yao; Rongbiao Lu; Yizhen Zhang; Ya Zhang; Chenyang Zhao; Rongchun Lin; Zhongqiu Lin
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

Review 2.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

3.  [The new S3 guideline "Prevention of cervical carcinoma" : What is important for pathology?]

Authors:  D Schmidt
Journal:  Pathologe       Date:  2018-05       Impact factor: 1.011

4.  CD66+ cells in cervical precancers are partially differentiated progenitors with neoplastic traits.

Authors:  Chitra Pattabiraman; Shiyuan Hong; Vignesh K Gunasekharan; Annapurna Pranatharthi; Jeevisha Bajaj; Sweta Srivastava; H Krishnamurthy; Aswathy Ammothumkandy; Venkat G Giri; Laimonis A Laimins; Sudhir Krishna
Journal:  Cancer Res       Date:  2014-09-29       Impact factor: 12.701

Review 5.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

6.  Cervical cancer: squamocolumnar junction ablation--tying up loose ends?

Authors:  Michael Herfs; Christopher P Crum
Journal:  Nat Rev Clin Oncol       Date:  2015-06-02       Impact factor: 66.675

7.  Establishment and optimization of epithelial cell cultures from human ectocervix, transformation zone, and endocervix optimization of epithelial cell cultures.

Authors:  Han Deng; Sumona Mondal; Shantanu Sur; Craig D Woodworth
Journal:  J Cell Physiol       Date:  2019-01-04       Impact factor: 6.384

8.  MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma.

Authors:  Seija I Vento; Lauri Jouhi; Hesham Mohamed; Caj Haglund; Antti A Mäkitie; Timo Atula; Jaana Hagström; Laura K Mäkinen
Journal:  Virchows Arch       Date:  2018-05-02       Impact factor: 4.064

Review 9.  Role of plasmonics in detection of deadliest viruses: a review.

Authors:  Foozieh Sohrabi; Sajede Saeidifard; Masih Ghasemi; Tannaz Asadishad; Seyedeh Mehri Hamidi; Seyed Masoud Hosseini
Journal:  Eur Phys J Plus       Date:  2021-06-20       Impact factor: 3.911

10.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

Authors:  Laia Alemany; Maëlle Saunier; Isabel Alvarado-Cabrero; Beatriz Quirós; Jorge Salmeron; Hai-Rim Shin; Edyta C Pirog; Núria Guimerà; Gustavo Hernandez-Suarez; Ana Felix; Omar Clavero; Belen Lloveras; Elena Kasamatsu; Marc T Goodman; Brenda Y Hernandez; Jan Laco; Leopoldo Tinoco; Daan T Geraets; Charles F Lynch; Vaclav Mandys; Mario Poljak; Robert Jach; Josep Verge; Christine Clavel; Cathy Ndiaye; JoEllen Klaustermeier; Antonio Cubilla; Xavier Castellsagué; Ignacio G Bravo; Michael Pawlita; William G Quint; Nubia Muñoz; Francesc X Bosch; Silvia de Sanjosé
Journal:  Int J Cancer       Date:  2014-05-30       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.